RSV Immunisation Pathfinder 2.0 Programme
A new ‘path finder’ programme is being introduced to ensure that infants are protected, and hospital services are not put under pressure with avoidable RSV related illness in infants.
A medication called nirsevimab protects babies from RSV.
Nirsevimab is a monoclonal antibody that offers passive immunity to infants during the RSV season. An antibody is a special protein that helps fight off infections. A monoclonal antibody is one that has been made in a laboratory to fight off a specific infection.
Nirsevimab has been approved by the European Medicines Agency (EMA). It is recommended by the Department of Health, the HSE and the National Immunisation Advisory Committee (NIAC).
Frequently Asked Questions about the RSV Immunisation Pathfinder Programme